SCI时时刷

search
+
Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
Multiple Myeloma (MM) is characterized by a great clinical and genetic heterogeneity [1]. The disease rem...
ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
Deletion of ABL1 was detected in a cohort of hematologic malignancies carrying AML1-ETO and NUP98 fusion proteins. Abl1...
CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults w...
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
Bortezomib, lenalidomide, and dexamethasone induction chemotherapy (VRd), followed by autologous stem cell transplantation...
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory...
Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Faculty of Medicine, Univeristy of Iceland, Reykjavík, IcelandSæmundur Rögnvaldsson, Thorvardur Jon Love, Sigrun Thorstein...
Multiple myeloma with t(11;14): impact of novel agents on outcome
Multiple myeloma with t(11;14): impact of novel agents on outcome
Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well establishe...
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
The basis of the NCCN recommendation is that 2G-TKIs lead to improved molecular and cytogenetic responses in CML patients....
MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
The paracaspase mucosa-associated lymphoid tissue 1 (MALT1) is a protease and scaffold protein essential in propagating B-...
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
The COVID-19 pandemic has had global healthcare impacts, including high mortality from SARS-CoV-2 infection in cancer pati...
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), formerly known as agranular CD4+/CD56+ hematodermic...
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
We identified 39 MM patients who received BsAb therapy at our centre with median follow-up of 152 (IQR 51–277) days. The m...
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Competing interests PM received honoraria from Bristol Myers Squibb/Celgen...
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is ...
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatmen...
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
Minimal residual disease (MRD) assessment has been established as a prognostic indicator for multiple mye...
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
Competing interests MD serves as Consultant for Amgen, Celgene, Janssen, K...
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
Blast-phase transformation in myeloproliferative neoplasms (MPN-BP) occurs at rates of 3.9, 2.6, and 9.3%...
Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance
Monoclonal gammopathy of undetermined significance (MGUS) is a benign hematological condition with the potential to progre...
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Constant challenges for the treatment of mantle cell lymphoma (MCL) remain to be recurrent relapses and therapy resistance...
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
Multiple myeloma (MM), an incurable plasma cell malignancy, is the second most common form of blood cance...
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
These authors contributed equally: Keiji Kurata, Anna James-Bott.Jerome Lipper Multiple Myeloma Center, LeBow Institute fo...
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpr...
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma...
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
Somatic mutations in calreticulin (CALR), encoding for the reticulum-endoplasmic-associated Ca2+-binding ...
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Functional perturbations of the cohesin complex with subsequent changes in chromatin structure and replication are reporte...
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in new treatments in rec...
DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
While chemoimmunotherapy has been the standard treatment for chronic lymphocytic leukemia (CLL), it has b...
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
Patients with hematologic diseases receiving anti-CD20 monoclonal antibodies show a low seroconversion ra...
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway
Alternative splicing plays a pivotal role in tumorigenesis and proliferation. However, its pattern and pathogenic role has...
阅读更多
format_indent_increase